EFPIA Patient Organization Reporting Methodological Note

Introduction
This document summarizes the methodology used in preparing Pfizer’s disclosure report on Transfers of Value to Patient Organizations, in accordance with the EFPIA Code of Practice.

Definitions
Patient Organization (PO): non-for-profit legal person/entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and which business address, place of incorporation or primary place of operation is in Europe.

Transfer of Value (ToV): Financial support and/or significant indirect/non-financial support provided by Pfizer to a Patient Organization:

- the monetary value of financial support and of invoiced costs.
- the non-monetary benefit that the PO receives when the non-financial support cannot be assigned to a meaningful monetary value

Europe: Includes those countries in which the EFPIA Member Associations’ National Codes apply.

Reporting Period: covers a full calendar year

Time of Disclosure: Disclosures must be made within 6 months after the end of the relevant Reporting Period and the information disclosed must remain in the public domain for a minimum of 3 years after the time such information is first disclosed. The general deadline for disclosures is 30 June.

Disclosures

National level
National association codes are in place to implement the EFPIA Code. Pfizer.com hosts either a link to POs’ ToV national disclosures or PDF documents with national disclosures (in some cases both).

European or international level
At a European regional level, we also provide details of ToV to all European regional POs. ToV to international (global) patient organisations based in Europe are also included in this process. In this document, references to ‘European POs’ can thus be taken to mean ‘European and international (global)’. For the purposes of transparency, we also voluntarily disclose ToV made to multi-stakeholder organisations who are engaged in substantial work with POs; this is included as an annex to the main declaration. Some payments are initiated by Pfizer in one year, but only paid to the recipient in the next. As the Belgian legislation demands that the payment be registered in the year it is made, we follow this approach at European level.